查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018538

感染疾病體外診斷市場：依產品、技術、病原體、應用和最終用戶分類－2026-2032年全球市場預測

Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，感染疾病體外診斷市場價值將達到 266.2 億美元，到 2026 年將成長至 282.4 億美元，到 2032 年將達到 409.8 億美元，複合年成長率為 6.35%。

主要市場統計數據
基準年 2025 266.2億美元
預計年份：2026年 282.4億美元
預測年份 2032 409.8億美元
複合年成長率 (%) 6.35%

在快速識別病原體是控制疫情爆發甚至預防流行病的關鍵所在，感染疾病體外診斷已成為公共衛生基礎設施的基石。檢查室決策者越來越依賴先進的儀器和整合服務解決方案，以提供及時、準確且經濟高效的檢測結果。在新型分子技術、自動化和數位資料管理整合的推動下，該領域正經歷著從基礎微生物培養基到先進的次世代定序平台的根本性變革。

此外，公共衛生機構和醫療服務提供者要求在不犧牲靈敏度和特異性的前提下提高檢測處理能力。這推動了試劑化學、檢測設計和儀器易用性的持續創新。同時，全球監管機構正在完善核准流程，將診斷準確性和病人安全作為首要任務，這進一步提高了對健全品管系統的需求。因此，相關人員必須在複雜的監管環境下，充分利用新興技術的潛力，以保持競爭力，並滿足全球對快速感染疾病監測和應對的需求。

技術、法規和市場引入方面的重大變革正在重新定義全球感染疾病的體外診斷策略。

隨著新技術的湧現和法規結構的不斷完善，感染疾病體外診斷領域正經歷模式轉移。等溫擴增和高通量定序的進步使得病原體檢測更加快速全面，而數位免疫檢測平台則透過整合人工智慧來提高結果解讀的準確性。因此，分散式檢查模式正在興起，使診斷能力更貼近臨床實踐，並有助於早期療育策略的實施。

對 2025 年美國關稅對感染疾病體外診斷產業供應鏈、成本和競爭的影響進行全面分析。

美國2025年實施的新關稅將對進口診斷設備和耗材帶來巨大的成本壓力。檢查室和診斷設備製造商正努力應對自動化培養系統、免疫檢測分析儀和分子檢測試劑等設備的採購成本上漲。因此，許多機構正在重新審視其供應商組合和籌資策略，以減輕供應鏈中斷的影響並維持財務穩健。

透過關鍵市場細分洞察，揭示感染疾病（體外診斷試劑）的產品、技術、病原體、應用和最終用戶趨勢。

我們的感染疾病診斷產品組合涵蓋儀器、試劑、試劑盒、軟體和服務，每一項都在檢查室工作流程中發揮至關重要的作用。儀器產品範圍廣泛，從自動化微生物培養系統到針對高通量檢測最佳化的先​​進免疫檢測和PCR分析儀，應有盡有。我們的試劑和試劑盒產品線包括免疫檢測盒、針對各種病原體最佳化的微生物培養基，以及專為精確分子擴增設計的高靈敏度PCR試劑。我們的服務包括：提供諮詢服務以支援檢查室驗證流程；提供資料管理平台，確保安全且有效率地處理大型資料集；以及提供維護支援服務，以維持儀器效能並最大限度地減少停機時間。

區域分析：美洲、歐洲、中東和非洲以及亞太地區感染疾病診斷的機會與挑戰

憑藉健全的醫療衛生基礎設施和充足的公共衛生資金支持，美洲在尖端診斷舉措的應用方面繼續發揮主導作用。受大規模篩檢計畫和持續監測活動的需求驅動，該地區正在快速採用自動化免疫檢測系統和分子檢測解決方案。同時，關稅調整導致的供應鏈重組迫使企業加強在北美和南美的本地夥伴關係和生產能力。

對推動感染疾病體外診斷領域成長的主要企業的創新、夥伴關係和擴張舉措進行策略評估。

感染疾病診斷領域的主要企業正透過在檢測方法開發、自動化和數位化整合方面的持續創新來推動成長。儀器製造商和試劑開發商之間的策略合作正在打造捆綁式解決方案，從而簡化採購流程並縮短驗證週期。與此同時，成熟的跨國公司正透過收購和合資企業擴大企業發展覆蓋範圍並獲得利基技術。此外，新興的專業公司正在快速分子檢測和人工智慧免疫檢測等高成長領域建立強大的市場地位。

為行業領導者提供實用建議，以應對感染疾病體外診斷市場的新趨勢，最佳化運營，並增強競爭力。

為了保持競爭優勢，產業領導者應優先考慮模組化平台架構，以實現快速偵測部署和無縫擴充性。投資於靈活的製造流程並建立多層供應商網路，有助於企業增強供應鏈韌性，並降低未來貿易政策變化的影響。與合約開發和製造合作夥伴建立策略夥伴關係，可以進一步加快產品上市速度，同時降低資本支出。

採用嚴謹的調查方法，利用資料收集、分析技術和檢驗流程來支持感染疾病診斷市場研究。

本研究整合了大量二手研究成果，包括對同行評審學術期刊、監管出版刊物和企業資訊披露的仔細審查。研究人員對診斷、公共衛生和研究機構的高級管理人員、檢查室經理和關鍵意見領袖（KOL）進行了結構化訪談，以檢驗研究結果。此外，研究人員還將定量數據與案例研究和試點實施的真實世界數據進行交叉比對，以確保研究結果的準確性和有效性。

為感染疾病體外診斷領域的相關人員提供權威見解，重點介紹關鍵發現、市場影響和策略考量。

總之，在技術突破、監管環境變化和貿易政策演變的推動下，感染疾病體外診斷產業正處於關鍵的十字路口。隨著檢查室和製造商適應新的關稅環境，採購和生產方面的策略重組將變得日益重要。市場區隔洞察表明，需要建立涵蓋儀器、試劑和數位化服務的多元化產品組合，以滿足終端用戶的多樣化需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：感染疾病體外診斷試劑市場：依產品分類

  • 裝置
    • 自動化培養系統
    • 免疫檢測裝置
    • PCR裝置
  • 試劑和試劑盒
    • 免疫檢測盒
    • 微生物培養基
    • PCR試劑
  • 軟體服務
    • 諮詢服務
    • 資料管理軟體
    • 維護和支援服務

第9章：感染疾病體外診斷試劑市場：依技術分類

  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 螢光免疫分析
    • 橫向流動化驗
  • 微生物培養
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • 聚合酵素鏈鎖反應

第10章：感染疾病體外診斷試劑市場－依病原體分類

  • 細菌
    • 腸桿菌科
    • 結核分枝桿菌
    • 金黃色葡萄球菌
  • 真菌
  • 寄生蟲
  • 病毒
    • 肝炎病毒
    • 人類免疫力缺乏病毒
    • 流感病毒

第11章感染疾病體外診斷試劑市場：依應用領域分類

  • 診斷
  • 流行病學調查
  • 監測
  • 篩檢

第12章感染疾病體外診斷試劑市場：依最終用戶分類

  • 學術研究機構
  • 診所
  • 醫院
  • 檢查室

第13章：感染疾病體外診斷試劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章感染疾病體外診斷試藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章感染疾病體外診斷試劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國感染疾病體外診斷市場

第17章：中國感染疾病體外診斷試劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Epitope Diagnostics, Inc.
  • F. Hoffmann La-Roche Ltd.
  • Grifols, SA
  • Hologic, Inc.
  • Illumina, Inc.
  • InBios International, Inc.
  • Koninklijke Philips NV
  • Merck KGaA
  • Meril Life Sciences Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Qiagen NV
  • Quest Diagnostics
  • Quidel Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Vela Diagnostics
Product Code: MRR-A339DAEFAD44

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 26.62 billion in 2025 and is projected to grow to USD 28.24 billion in 2026, with a CAGR of 6.35%, reaching USD 40.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.62 billion
Estimated Year [2026] USD 28.24 billion
Forecast Year [2032] USD 40.98 billion
CAGR (%) 6.35%

In an environment where rapid pathogen identification can mean the difference between containment and outbreak, in-vitro diagnostics for infectious diseases have become pivotal to public health infrastructure. Laboratory decision-makers are increasingly reliant on advanced instruments and integrated service solutions to deliver timely, accurate, and cost-effective results. Driven by the convergence of novel molecular techniques, automation, and digital data management, the sector is experiencing a profound transformation that extends from basic microbial culture media to sophisticated next-generation sequencing platforms.

Furthermore, public health agencies and healthcare providers are demanding improved throughput without sacrificing sensitivity or specificity. This has spurred continuous innovation in reagent chemistry, assay design, and instrumentation ergonomics. At the same time, regulatory agencies around the world are refining approval pathways, prioritizing diagnostic accuracy and patient safety, which reinforces the need for robust quality management systems. As a result, industry stakeholders must navigate complex compliance landscapes while harnessing the potential of emerging technologies to stay competitive and address global needs for rapid infectious disease surveillance and response.

Critical Transformative Shifts in Technology, Regulation, and Market Adoption Redefining Infectious Diseases In-Vitro Diagnostic Strategies Worldwide

The landscape of infectious diseases in-vitro diagnostics is undergoing a paradigm shift as novel technologies gain traction and regulatory frameworks evolve. Advances in isothermal amplification and high-throughput sequencing are enabling faster, more comprehensive pathogen detection, while digital immunoassay platforms are integrating artificial intelligence to enhance result interpretation. As a result, decentralized testing models are emerging, bringing diagnostic capabilities closer to point-of-care settings and enabling earlier intervention strategies.

Simultaneously, regulatory bodies are harmonizing global approval processes, which facilitates more streamlined market access but also raises the bar for clinical validation and post-market surveillance. This alignment encourages international collaboration, accelerates technology transfer, and drives investment into standardized manufacturing practices. Consequently, stakeholders must recalibrate their development roadmaps and supply chain strategies to accommodate both heightened regulatory scrutiny and the growing demand for rapid, multiplexed diagnostic solutions.

Comprehensive Analysis of the 2025 United States Tariff Effects on Supply Chains, Costs, and Competitive Dynamics within the Infectious Diseases IVD Industry

The implementation of new United States tariff measures in 2025 has introduced significant cost pressures on imported diagnostic instruments and consumables. Laboratories and diagnostic companies are grappling with increased procurement expenses for automated culture systems, immunoassay analyzers, and molecular assay reagents. Consequently, many organizations are reevaluating their vendor portfolios and sourcing strategies to mitigate supply chain disruptions and maintain financial resilience.

In response, several manufacturers have accelerated domestic production initiatives and formed strategic alliances with local suppliers to reduce import dependency. This realignment of supply networks is reshaping the competitive landscape, with vertically integrated firms gaining an advantage through in-house reagent and instrument production. Over the long term, the tariff impact may lead to increased pricing transparency and a shift towards more localized manufacturing footprints, enabling faster response times to emerging public health threats.

Insights from Key Market Segmentation Revealing Distinct Product, Technology, Pathogen, Application, and End User Dynamics in Infectious Diseases IVD

The product spectrum in infectious diseases diagnostics encompasses instruments, reagents and kits, as well as software and services, each playing a vital role in laboratory workflows. Instruments range from automated microbial culture systems to advanced immunoassay and PCR analyzers tailored for high-throughput testing. Reagent and kit offerings include immunoassay test kits, microbial culture media optimized for a variety of pathogens, and highly sensitive PCR reagents designed for precise molecular amplification. On the services side, consulting expertise guides laboratory validation processes, data management platforms ensure secure and efficient handling of large datasets, and maintenance support services uphold instrument performance and minimize downtime.

Technology segmentation reveals the predominance of immunoassays for rapid antigen and antibody detection, microbiology culture techniques for traditional pathogen isolation, and molecular diagnostics for comprehensive genomic analysis. Within immunoassays, modalities such as chemiluminescence, enzyme-linked immunosorbent assays, fluorescence immunoassays, and lateral flow formats each offer distinct operational advantages. Molecular diagnostics extend from isothermal amplification methods to next-generation sequencing and polymerase chain reaction workflows, supporting everything from point-of-care screening to extensive epidemiological studies.

Pathogen-focused insights demonstrate that bacterial testing demand, driven by Enterobacteriaceae, Mycobacterium tuberculosis, and Staphylococcus aureus assays, remains strong alongside viral diagnostics targeting hepatitis, HIV, and influenza viruses. Application-based analysis underscores critical use cases in diagnosis, epidemiological surveillance, ongoing monitoring of treatment efficacy, and large-scale screening initiatives. End-user segmentation highlights that academic research institutions spearhead innovation, clinics and hospitals deliver patient-centric testing, and specialized laboratories provide high-complexity services, collectively forming an ecosystem that responds to evolving infectious disease challenges.

Regional Analysis Unveiling Opportunities and Challenges across Americas, Europe Middle East Africa, and Asia Pacific in Infectious Diseases Diagnostics

The Americas continue to lead in the adoption of cutting-edge diagnostic platforms, supported by robust healthcare infrastructure and extensive funding for public health initiatives. This region exhibits rapid uptake of automated immunoassay systems and molecular testing solutions, driven by the need for large-scale screening programs and ongoing surveillance efforts. At the same time, supply chain recalibrations following tariff changes have prompted companies to strengthen local partnerships and manufacturing capabilities within North and South America.

In Europe, the Middle East, and Africa, regulatory harmonization under the European In-Vitro Diagnostic Regulation is creating a unified framework for product approval, enhancing market predictability. Nonetheless, funding constraints in certain emerging markets and logistical hurdles in remote areas are shaping differential adoption rates. Meanwhile, Asia-Pacific is experiencing remarkable growth due to government-led screening campaigns, expanding laboratory networks in urban centers, and a growing emphasis on cost-effective assay solutions. Local manufacturing ecosystems are evolving rapidly, enabling faster product launches and fostering competitive pricing strategies to meet diverse regional needs.

Strategic Evaluation of Leading Players' Innovation, Partnership, and Expansion Initiatives Driving Growth in the Infectious Diseases In-Vitro Diagnostic Sector

Leading players in the infectious diseases diagnostics space are driving growth through continuous innovation in assay development, automation, and digital integration. Strategic collaborations between instrument manufacturers and reagent developers are forging bundled solutions that simplify procurement and reduce validation timelines. At the same time, acquisitions and joint ventures are enabling established multinationals to expand their geographic footprint and access niche technologies, while emerging specialized firms are carving out positions in high-growth segments such as rapid molecular assays and AI-enhanced immunoassays.

Furthermore, companies are investing in digital health platforms that aggregate testing data to deliver real-time insights into outbreak trends, antimicrobial resistance patterns, and patient outcomes. These initiatives not only enhance end-user engagement but also foster recurring revenue streams through software subscriptions and service contracts. As the competitive landscape intensifies, differentiation will hinge on the ability to offer comprehensive solutions that seamlessly integrate instruments, consumables, and data analytics into a unified diagnostic ecosystem.

Actionable Recommendations for Industry Leaders to Navigate Emerging Trends, Optimize Operations, and Enhance Competitiveness in Infectious Disease IVD Market

To maintain a competitive edge, industry leaders should prioritize modular platform architectures that enable rapid assay deployment and seamless scalability. By investing in flexible manufacturing processes and establishing multi-tiered supplier networks, organizations can enhance supply chain resilience and mitigate the impact of future trade policy shifts. Strategic collaboration with contract development and manufacturing partners can further accelerate time to market while reducing capital outlay.

In parallel, integrating data management and analytics into diagnostic offerings will empower laboratories to derive actionable insights and improve operational efficiency. Companies that foster open interoperability standards and invest in cybersecurity measures will build trust and drive adoption of digital solutions. Moreover, engaging proactively with regulatory bodies to shape evolving frameworks can streamline approval processes and provide early visibility into compliance requirements.

Finally, expanding into underserved geographies through public-private partnerships and capacity-building initiatives will unlock new growth opportunities. By tailoring product portfolios to local clinical needs and price sensitivities, organizations can strengthen their market presence and contribute to global health security initiatives.

Rigorous Research Methodology Leveraging Data Collection, Analysis Techniques, and Validation Processes Underpinning the Infectious Diseases Diagnostics Market Study

This study synthesizes insights from extensive secondary research, including examination of peer-reviewed journals, regulatory publications, and corporate disclosures. To validate findings, structured interviews were conducted with senior executives, laboratory directors, and key opinion leaders across diagnostics, public health, and research institutions. Quantitative data points were triangulated with real-world evidence from case studies and pilot implementations to ensure accuracy and relevance.

Analytical techniques encompassed comparative benchmarking of assay performance, scenario analysis to assess tariff impact under various trade regimes, and qualitative assessment of emerging technology pipelines. A multi-stage validation process was employed, encompassing internal peer review, expert advisory board feedback, and cross-referencing with regional regulatory updates. This rigorous approach ensures that the conclusions and recommendations reflect both current market realities and anticipated industry trajectories.

Conclusive Insights Highlighting Key Findings, Market Implications, and Strategic Considerations for Stakeholders in Infectious Disease In-Vitro Diagnostics

In conclusion, the infectious diseases in-vitro diagnostics sector is poised at a critical juncture, driven by technological breakthroughs, shifting regulatory landscapes, and evolving trade policies. As laboratories and manufacturers adapt to new tariff environments, strategic realignments in sourcing and production will become increasingly important. The segmentation insights underscore the necessity for diversified portfolios, spanning instruments, reagents, and digital services, to meet heterogeneous end-user demands.

Regional dynamics reveal that while established markets will continue to benefit from advanced diagnostic infrastructures, high-growth potential lies in emerging economies that are scaling up screening and surveillance capabilities. Ultimately, success in this market will depend on the ability to integrate innovative assay platforms with robust data analytics, maintain compliance amidst tightening regulations, and pursue agile partnerships that drive value across the diagnostic continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 8.1. Instruments
    • 8.1.1. Automated Culture Systems
    • 8.1.2. Immunoassay Instruments
    • 8.1.3. PCR Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Immunoassay Kits
    • 8.2.2. Microbial Culture Media
    • 8.2.3. PCR Reagents
  • 8.3. Software & Services
    • 8.3.1. Consulting Services
    • 8.3.2. Data Management Software
    • 8.3.3. Maintenance & Support Services

9. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 9.1. Immunoassays
    • 9.1.1. Chemiluminescence Immunoassay
    • 9.1.2. Enzyme Linked Immunosorbent Assay
    • 9.1.3. Fluorescence Immunoassay
    • 9.1.4. Lateral Flow Assay
  • 9.2. Microbiology Culture
  • 9.3. Molecular Diagnostics
    • 9.3.1. Isothermal Amplification
    • 9.3.2. Next Generation Sequencing
    • 9.3.3. Polymerase Chain Reaction

10. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen

  • 10.1. Bacterial
    • 10.1.1. Enterobacteriaceae
    • 10.1.2. Mycobacterium Tuberculosis
    • 10.1.3. Staphylococcus Aureus
  • 10.2. Fungal
  • 10.3. Parasitic
  • 10.4. Viral
    • 10.4.1. Hepatitis Virus
    • 10.4.2. Human Immunodeficiency Virus
    • 10.4.3. Influenza Virus

11. Infectious Diseases In-Vitro Diagnostics Market, by Application

  • 11.1. Diagnosis
  • 11.2. Epidemiological Surveillance
  • 11.3. Monitoring
  • 11.4. Screening

12. Infectious Diseases In-Vitro Diagnostics Market, by End User

  • 12.1. Academic Research Institution
  • 12.2. Clinic
  • 12.3. Hospital
  • 12.4. Laboratory

13. Infectious Diseases In-Vitro Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Infectious Diseases In-Vitro Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Diseases In-Vitro Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Infectious Diseases In-Vitro Diagnostics Market

17. China Infectious Diseases In-Vitro Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. bioMerieux SA
  • 18.9. Danaher Corporation
  • 18.10. DiaSorin S.p.A
  • 18.11. Epitope Diagnostics, Inc.
  • 18.12. F. Hoffmann La-Roche Ltd.
  • 18.13. Grifols, S.A.
  • 18.14. Hologic, Inc.
  • 18.15. Illumina, Inc.
  • 18.16. InBios International, Inc.
  • 18.17. Koninklijke Philips N.V.
  • 18.18. Merck KGaA
  • 18.19. Meril Life Sciences Pvt. Ltd.
  • 18.20. OraSure Technologies, Inc.
  • 18.21. Qiagen N.V.
  • 18.22. Quest Diagnostics
  • 18.23. Quidel Corporation
  • 18.24. Siemens Healthineers AG
  • 18.25. Sysmex Corporation
  • 18.26. Thermo Fisher Scientific Inc.
  • 18.27. Trinity Biotech PLC
  • 18.28. Vela Diagnostics

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 255. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 262. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 263. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 264. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS,